Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06190197

Prophylactic Antibiotics in Cystectomy With Diversion

Muscle-Invasive Bladder Carcinoma Clinical Trial

Official title:
Prophylactic Antibiotics in Radical Cystectomy With Urinary Diversion

Clinical Trial Summary

Using a randomized 2 arm design, this study is being conducted to test for non-inferiority of no prophylactic antibiotic therapy versus the prophylactic oral antibiotic, nitrofurantoin, through comparison of rates of postoperative urinary tract infections within the 90-day postoperative period in patients with muscle invasive bladder cancer who undergo radical cystectomy with urinary diversion.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06190197
Study type Interventional
Source University of Minnesota
Contact Maressa Twedt
Phone 612-626-6661
Email twedt050@umn.edu
Status Recruiting
Phase Early Phase 1
Start date May 13, 2024
Completion date October 15, 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05097404 - Clinical Utility of VI-RADS in Diagnosis of MIBC
Recruiting NCT05483868 - A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer Phase 1
Not yet recruiting NCT04966130 - Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.
Active, not recruiting NCT04610671 - Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC Phase 1
Recruiting NCT06341400 - RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients Phase 1/Phase 2
Recruiting NCT05203913 - Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT05790850 - Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) N/A
Recruiting NCT05833867 - Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer Phase 1
Recruiting NCT05295992 - Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach N/A
Recruiting NCT06215976 - The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer Phase 4
Recruiting NCT05028660 - AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study
Not yet recruiting NCT06417190 - Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology Phase 2
Not yet recruiting NCT04909775 - Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT04876313 - An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) Phase 2
Not yet recruiting NCT04686149 - a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients
Active, not recruiting NCT05630131 - ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
Recruiting NCT06170177 - Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
Terminated NCT05221827 - Clinical Performance Evaluation of the C2i-Test
Recruiting NCT06257017 - Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial Phase 2
Recruiting NCT05767528 - Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection